$ADTN

BlackRock, Inc. reported a voting rights notification for Adtran Holdings, Inc. (ADTN) under German securities law. As of November 6, 2026, BlackRock's total voting rights reached 11.99%, including 8.83% from shares and 3.15% from instruments. This notification was triggered by a voluntary group notification due to a threshold being crossed at the subsidiary level.

Goldman Sachs reported a major-holdings notification for Adtran Holdings (ADTN) on Nov. 5, 2026, but did not disclose the percentage or total position. The filing lacks details on whether the stake was increased or reduced, according to the company.

Santo Timothy P (SVP of Finance; CFO) purchased 17,820 shares of ADTRAN Holdings, Inc. (ADTN) at $4.16 on 2026-11-06.

STANTON THOMAS R (Chairman & CEO) purchased 150,000 shares of ADTRAN Holdings, Inc. (ADTN) at $4.01 ($0.60M total) on 2026-11-06.

Analyst rating changes drove significant stock moves this week. Inovio (INO) surged 213.7% after FDA approval, but later fell 36%. Ibotta (IBTA) rose 20.5% on an upgrade. Amdocs (DOX) dropped 30.1% after guidance cuts. LegalZoom (LZ) fell 13.7% on a downgrade and missed earnings. NerdWallet (NRDS) declined 31.0% following a downgrade and earnings miss.

Adtran Holdings Inc (ADTN) reported Q3 2026 revenue of $281.2M, slightly below guidance due to supply constraints. Non-GAAP gross margin was 42.1%, including a 200-basis point tariff refund benefit. Operating cash flow was negative $24.5M. Q4 guidance indicates a significant sequential decline in non-GAAP operating margin to 1-5%.

Needham reduced its price target on Adtran (ADTN) to $9.00 from $14.00, citing supply chain issues. The stock is near its 52-week low, down 32% in a week. Q3 2026 revenue declined 2% below estimates, though EPS beat expectations. Q4 guidance was below consensus. Optical segment sales rose 11% YoY, but other segments were flat. Rosenblatt downgraded ADTN to Neutral with a $6.25 target.

B. Riley Securities kept its Buy rating on Adtran Holdings but reduced its price target to $14 from $21, a 33.3% cut. This implies a 176.7% upside from the Nov 3 close of $5.06. Other recent analyst targets for the company range from $6.25 to $9.

Evercore ISI Group kept Adtran Holdings at Outperform but reduced its price target from $11 to $8, a 27.3% cut. This implies a 58.1% upside from the Nov 3 close of $5.06, according to the firm.

Rosenblatt downgraded ADTRAN (ADTN) to Neutral from Buy with a $6.25 price target, citing excessive telco exposure and execution challenges. The stock, trading at $5.05, has fallen 66% in six months. ADTRAN's Q3 2026 revenue missed estimates at $281.2M, but EPS beat at $0.09. The company faces supply constraints and margin pressures but has upside drivers in 2027-2028.